Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive MS trials: Lessons learned.

Carmen Tur1, Xavier Montalban2

  • 1The Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London, London, UK/Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|October 19, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.

Brain : a journal of neurology·2026
Same author

High-efficacy therapy and progression independent of relapse and MRI activity in multiple sclerosis.

Brain : a journal of neurology·2026
Same author

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Lancet (London, England)·2026
Same author

Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity.

JAMA network open·2026
Same author

Optic nerve imaging with OCT predicts disease progression and monitors brain and spinal atrophy in primary progressive multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Interaction between smoking and <i>HLA-A*02:01</i> in multiple sclerosis progression.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Recent advances show modest benefits for progressive multiple sclerosis (MS) treatments, primarily in patients with active inflammation. Future trial designs require targeted mechanisms, specific patient selection, and sensitive outcome measures for effective progressive MS therapies.

Area of Science:

  • Neurology
  • Clinical Trials
  • Immunology

Background:

  • Progressive multiple sclerosis (MS) has historically lacked effective treatments.
  • Recent trials in 2016 identified four drugs with beneficial effects in progressive MS, though successes were modest.
  • Current successes are largely limited to patients with active inflammation, using potent anti-inflammatory agents.

Purpose of the Study:

  • To summarize recent findings in progressive MS treatment.
  • To identify key lessons for designing future clinical trials in progressive MS.
  • To discuss strategies for improving the efficacy of progressive MS therapies.

Main Methods:

  • Review of phase 2 and phase 3 clinical trial data for progressive MS treatments.
  • Analysis of drug mechanisms of action in relation to MS pathogenesis.
Keywords:
MRIMultiple sclerosisclinical trialdisease modifying therapiesoutcome measurementtreatment response

Related Experiment Videos

  • Evaluation of trial design elements, including patient selection and outcome measures.

    • Main Results:

    • Modest treatment benefits observed in progressive MS, mainly in patients with active inflammation.
    • Identification of critical factors for successful future trial design.
    • Emphasis on the need for treatments targeting specific progressive MS pathogenic mechanisms.

    Conclusions:

    • Future progressive MS treatments must align with specific disease mechanisms.
    • Careful selection of trial populations, including younger patients with shorter disease duration, is crucial.
    • Highly sensitive outcome measures and intelligent trial designs are essential for detecting treatment effects in progressive MS.